144 related articles for article (PubMed ID: 14714315)
1. [Measurement of soluble CD44v6 in peripheral blood as assistant diagnosis of invasive pituitary adenomas].
Kong YG; Su CB; Ren ZY; Wang RZ; Li GL; Dou WC; Zhang B; Tian SQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):698-701. PubMed ID: 14714315
[TBL] [Abstract][Full Text] [Related]
2. Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma.
Kong YG; Ren ZY; Su CB; Wang RZ; Ma WB; Lian W
Chin Med Sci J; 2004 Sep; 19(3):199-202. PubMed ID: 15506648
[TBL] [Abstract][Full Text] [Related]
3. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
4. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer.
Yamane N; Tsujitani S; Makino M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):232-8. PubMed ID: 10202279
[TBL] [Abstract][Full Text] [Related]
6. [Expressive level of vascular endothelial growth factor in peripheral blood in patients with pituitary adenomas].
Kong YG; Ren ZY; Su CB; Wang RZ; Xing B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):164-7. PubMed ID: 15171554
[TBL] [Abstract][Full Text] [Related]
7. [Expression and clinical significance of CD44v6 and sCD44v6 in gastric carcinoma].
Zhou DH; Ma ZM; Chen Y
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):833-7. PubMed ID: 18396641
[TBL] [Abstract][Full Text] [Related]
8. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
9. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
10. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
11. Study on the expression levels of CXCR4, CXCL12, CD44, and CD147 and their potential correlation with invasive behaviors of pituitary adenomas.
Xing B; Kong YG; Yao Y; Lian W; Wang RZ; Ren ZY
Biomed Environ Sci; 2013 Jul; 26(7):592-8. PubMed ID: 23895705
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
14. [Detection of serum epidermal growth factor receptor in the diagnosis of proliferation of pituitary adenomas].
Kong Y; Ren Z; Su C; Wang R
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):527-9. PubMed ID: 12133497
[TBL] [Abstract][Full Text] [Related]
15. [Invasive giant pituitary adenomas].
Matsko DE; Vogel G; Ulitin AIu; Oliushin VE; Moes G; Pergamenshchikov AA; Burnin KS; Safarov BI; Markova NV
Arkh Patol; 2007; 69(2):46-50. PubMed ID: 17642195
[TBL] [Abstract][Full Text] [Related]
16. Significance of leptin expression in invasive potential of pituitary adenomas.
Isono M; Inoue R; Kamida T; Kobayashi H; Matsuyama J
Clin Neurol Neurosurg; 2003 Apr; 105(2):111-6. PubMed ID: 12691803
[TBL] [Abstract][Full Text] [Related]
17. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between sCD44v6 expression and TCM differentiation type of gastric carcinoma patients and influence of weitai capsule on the expression].
Chen X; Ouyang XN; Dai XH; Chen MH; Lin QC
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Jan; 25(1):12-5. PubMed ID: 15719741
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
Chang SM; Xing RD; Zhang FM; Duan YQ
Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
